Department of Cancer Biology, University of Pennsylvania, Philadelphia, United States.
Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, United States.
Elife. 2021 Nov 30;10:e62644. doi: 10.7554/eLife.62644.
Tumors frequently exhibit aberrant glycosylation, which can impact cancer progression and therapeutic responses. The hexosamine biosynthesis pathway (HBP) produces uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), a major substrate for glycosylation in the cell. Prior studies have identified the HBP as a promising therapeutic target in pancreatic ductal adenocarcinoma (PDA). The HBP requires both glucose and glutamine for its initiation. The PDA tumor microenvironment is nutrient poor, however, prompting us to investigate how nutrient limitation impacts hexosamine synthesis. Here, we identify that glutamine limitation in PDA cells suppresses de novo hexosamine synthesis but results in increased free GlcNAc abundance. GlcNAc salvage via N-acetylglucosamine kinase (NAGK) is engaged to feed UDP-GlcNAc pools. expression is elevated in human PDA, and deletion from PDA cells impairs tumor growth in mice. Together, these data identify an important role for NAGK-dependent hexosamine salvage in supporting PDA tumor growth.
肿瘤经常表现出异常的糖基化,这可能影响癌症的进展和治疗反应。己糖胺生物合成途径(HBP)产生尿苷二磷酸 N-乙酰葡萄糖胺(UDP-GlcNAc),这是细胞中糖基化的主要底物。先前的研究已经确定 HBP 是胰腺导管腺癌(PDA)有前途的治疗靶点。HBP 的启动既需要葡萄糖又需要谷氨酰胺。然而,PDA 肿瘤微环境营养匮乏,促使我们研究营养限制如何影响己糖胺的合成。在这里,我们发现 PDA 细胞中的谷氨酰胺限制抑制了从头合成的己糖胺,但导致游离 GlcNAc 丰度增加。通过 N-乙酰葡萄糖胺激酶(NAGK)进行 GlcNAc 回收以供给 UDP-GlcNAc 池。在人类 PDA 中表达上调,并且从 PDA 细胞中缺失会损害小鼠中的肿瘤生长。这些数据共同确定了 NAGK 依赖性己糖胺回收在支持 PDA 肿瘤生长中的重要作用。